AKT1 and melanoma: Taken together, modulation of AKT during TIL's rapid expansion stage might contribute to a better clinical outcome, which would be especially meaningful for ovarian or cervical cancer that generally have a lower response rate of TIL‐based therapy compared to melanoma.